CPT code 38210 designates preparation of hematopoietic progenitor cells with minimized T-cell content to lower the risk of graft rejection in transplantation. This cellular product manipulation is central to hematopoietic stem cell and bone marrow transplant workflows and matters nationally because it affects transplant safety, perioperative immunologic outcomes, and payer coverage policies for complex cellular therapies. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of CPT code 38210 including clinical context for T-cell depletion, common sites of service, and the role this preparation plays in transplant programs. The publication summarizes payer coverage patterns, reimbursement benchmarks, and relevant policy considerations that influence access to T-cell–reduced HPC products. Additional sections provide procedural definitions, coding notes, and operational considerations for facilities that perform cellular product preparation. Data not available in the input will be indicated where applicable.